Navigation Links
Second Phase III Study of Avastin in 1st Line Metastatic Breast Cancer Meets its Primary Endpoint
Date:2/12/2008

- Results of This Trial Further Confirm the Benefit Avastin Brings to

Patients With Breast Cancer.

BASEL, Switzerland, Feb. 13 /PRNewswire/ -- Roche announced today that a phase III study in metastatic breast cancer investigating Avastin (bevacizumab) in combination with docetaxel chemotherapy compared to docetaxel alone, met its primary endpoint of improving the time patients live without their disease advancing.

The findings come from the first analysis of the phase III "Avastin and Docetaxel" ("AVADO", BO17708) study which investigated the addition of docetaxel to Avastin administered either at 7.5 or 15 mg/kg every 3 weeks. Both doses of Avastin in combination with chemotherapy showed statistically significant improvements in the time patients live without their disease advancing, as measured by progression-free survival, compared to chemotherapy alone. The study was not designed to compare the two Avastin-containing arms.

No new safety signals related to Avastin were observed in the trial.

Dr David Miles, medical oncologist, Mount Vernon Hospital, UK and principal investigator of AVADO, welcomed the news: "Each year more than one million women are diagnosed with breast cancer leading to over 400,000 deaths globally. This study confirms Avastin's effect of prolonging the time in which patients live without their disease getting worse in combination with a widely used chemotherapy partner -- this time gained is very precious."

The efficacy and safety data of AVADO will be presented at an upcoming medical meeting.

This second positive phase III trial follows the recently published landmark E2100 study, which formed the basis of European Commission approval of Avastin in combination with paclitaxel for the 1st line treatment of metastatic breast cancer in March 2007. Study E2100 showed that the addition of Avastin to paclitaxel resulted in a doubling of progression-free survival compared to p
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
3. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
4. Second Thoughts about Fluoride, Reports Scientific American
5. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
6. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
7. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
8. Immtech Reports Fiscal Second Quarter 2008 Results
9. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
10. Rcadias COR Analyzer Family of Products Receives Second FDA Clearance
11. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)..., , CHICAGO, Nov. 29 This... (RSNA) Scientific Assembly and Annual Meeting, FU...nce into the advanced visualization space with the...lding on its core strength in image processing by ... for both general radiographic and cardiovascular ...
(Date:11/27/2009)..., , Another option to prevent illne...,, SILVER SPRING, Md., Nov. 27 /PRNewswire-USNe...oday approved Agriflu for people ages 18 years and...s subtypes A and B. ,, (Logo: http://www.new...iflu, manufactured by Novartis Vaccines and Diagno...
(Date:11/27/2009)..., , CHICAGO, Nov. 27 ...ica (RSNA) annual meeting starting Sunday, Royal P...te a new range of healthcare imaging and informati...rities of patients and care providers, by deliveri...esire for value, modular price points and easy upg...
Breaking Medicine Technology:FUJIFILM Enters Advanced Visualization Market 2FUJIFILM Enters Advanced Visualization Market 3FUJIFILM Enters Advanced Visualization Market 4FDA Approves Agriflu Seasonal Influenza Vaccine 2Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 60856 1Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 60856 2Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 60856 3Caraco Pharmaceutical Laboratories Ltd Markets Generic Acular 28R 29 Ophthalmic Solution 6058 1Caraco Pharmaceutical Laboratories Ltd Markets Generic Acular 28R 29 Ophthalmic Solution 6058 2New Smells Etched in Brain 3A Study 60854 1New Smells Etched in Brain 3A Study 60854 2
...lorida,Technology, Research and Scholarship Board ...rcher Dr. Herbert Weissbach, distinguished,profess...y and,Biotechnology in the Charles E. Schmidt Coll...294 as part of the State University Research,Comme...URECAG was,established by the Florida Legislature ...
...rporation,(Amex: CVM ) announced today that it pr...s Evans conference on Immunogenicity in Amsterdam....r Vice President of Research,Cellular Immunology o...ritis vaccine CEL-2000 prevents or retards the per...s in an animal model of the disease. These new,fin...
Other Medicine Technology:Major State Grant Accelerates Research and Development of Novel Cancer Therapy 2Major State Grant Accelerates Research and Development of Novel Cancer Therapy 3Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 2Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 3Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 4
(Date:11/27/2009)...nce, Nov. 27 Team Garmin-Slipstrea...dicated to ethical sporting and developing the nex... that it will become Team Garmin-Transitions with ...or of the team. Transitions Optical is the world,s...g the most advanced photochromic technology in the...
(Date:11/27/2009)...oldings has announced that it has become a nationa...largest nonprofit organizations dedicated to arthr... Delray Beach, FL (Vocus) Novem...HO), a company specializing in the marketing and r..., has announced today that is has become a nationa...
(Date:11/27/2009)... medical, economic burdens, study predicts , ...ber of people with diabetes in the United States i... study predicts. , That would bring the total b...se, up from 23.7 million today. , , At the same ...ll triple, the study also warns, rising from an es...
(Date:11/27/2009)...lth™ announced today that Spectrum Health (G...Enterprise orthopedic templating solution and its ... (PRWEB) November 27, 2009 -- Voyant H...(Grand Rapids, Michigan) has licensed its TraumaCa...s TraumaCad Extend workflow solution, to allow its...
(Date:11/27/2009)... manufacturers who use medical load cells at the h...ars by bringing in technology partner Flintec earl...-active medical manufacturers are calling in Flint... projects, ensuring that progress will not be cons...y outdated technology. , ...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...dy published in the December issue of Arthritis an...llagen (CII) could have a vital role in the pathog...l inflammatory // joint condition. This protei...ifies itself and then proceeds to systematically d...
... Virginia - Researchers at the Virginia Commonweal...plasma lipoprotein in patients with advanced perio...k of heart disease in these patients. // Peri...ases including diabetes and cardiovascular disease...
...velling Asia and causing havoc the bird flu has sp...es have been detected in Ukraine. This has sen... // To ascertain the severity of the flu tes... called for by the Ukrainian president in some par...
...h sector of England has both doctors and nurses of... to be almost 20 percent.// The National Health S...a, from the Birmingham Children's Hospital, in the...n's health charity WellChild launched the competit...
...ity of Cincinnati (UC) research team comprising Sc...ws negative effect in brain tissue// 'at surprisin...e new studies are also the first to show that oest...eproductive functions,' 'BPA molecules are l...
...dy says that squinting at your computer screens is...ss of lubrication leading to eye strain, irritatio...niversity say that the less people blink the more ...te go way down," said lead researcher James Sheedy...
Other Medicine News:Health News:Severe Gum Disease Triples Heart Disease Risk 2Health News:Food packaging with Bisphenol A damages the brain 2
Sterilized TowerPack Refill System D200
Finntip Wide 10-200ul, Sterile
Finntip 200 Ext (Sterile)
MBP 200MicroPoint Design
Medicine Products: